Eli Lilly & Co. said it plans to begin commercial sales of its Covid-19 monoclonal antibody treatment to states, hospitals and other healthcare providers this month, as the federal government’s supply of the drug is nearly depleted.

The move marks a shift away from the way Lilly’s drug and most other Covid-19 treatments and vaccines have been distributed in the U.S. It will likely be the first test of whether the vaccines and treatments would remain accessible if shifted to a commercial market.

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Florida man pleads guilty to smuggling thousands of turtles to Hong Kong and Germany

A Florida man pleaded guilty to smuggling thousands of turtles to Germany and…

FBI resumes outreach to social media companies over foreign propaganda

The FBI has resumed some of its efforts to share information with…

Tesla Deliveries Rose 83% in the Latest Quarter

What to Read Next This post first appeared on wsj.com

Facebook banned ‘Boogaloo’-related groups — but new research suggests a ‘boomerang’ effect

Eighteen months after Facebook banned communities and users connected with the “Boogaloo”…